Investigating several routes does not establish that all resulting products are interchangeable. Route, formulation and the outcome being measured are inseparable parts of a drug study.
An early human hexarelin investigation examined GH-releasing activity after several administration routes. That establishes that route-specific responses were studied. It does not show that an arbitrary oral capsule, nasal preparation or research vial reproduces the intervention or provides equivalent clinical benefit.
The formulation is part of the evidence
A molecule's name alone does not describe how it reaches its biological target. The material, preparation and experimental conditions influence what question a route study can answer. Removing those details can make a mechanistic observation sound like a universal delivery claim.
Equivalence would also need a clearly defined standard. Similarity in one short hormone measurement is different from comparable exposure, consistent performance, safety or long-term outcomes. A claim must say which of these was actually evaluated.
This is why a route comparison should not be converted into a home preparation guide. Altering a product or repurposing an ingredient for another route introduces questions the study did not answer.
For laboratory research, the relevant work is matching the test material and documented method to the intended experiment. For medical treatment, formulation and substitution decisions require a licensed prescriber and pharmacist using an appropriate medicine.
This article does not rank routes, provide conversion factors or describe preparation techniques. The accessible abstract is enough to establish the study's scope, but full formulation and methods details would be essential before a more specific technical comparison.
The correct conclusion is that administration route has been a research variable for hexarelin. It is not that all route-labeled products are equivalent or suitable for human use. A well-cited article should preserve the formulation boundary rather than use one paper to endorse an entire product category.